SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Generate Biomedicines Reports Third Quarter 2026 Financial Results and Provides Business Update

GB-0895 is being evaluated in two Phase 3 severe asthma studies for dosing twice a year A single dos

GENB

Related stories